http://archneur.jamanetwork.com/ en-us Mon, 17 Dec 2012 00:00:00 GMT Tue, 01 Jan 2013 00:45:23 GMT Silverchair editor@archneur.jamanetwork.com webmaster@archneur.jamanetwork.com http://archneur.jamanetwork.com/article.aspx?articleID=792501 Sun, 01 Oct 2006 00:00:00 GMT Allen JA, Adlakha A, Bergethon PR. <span class="paragraphSection"><div class="boxTitle">Objective</div>To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor.<div class="boxTitle">Design</div>Case report/literature review.<div class="boxTitle">Setting</div>University hospital.<div class="boxTitle">Patient</div>A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.<div class="boxTitle">Results</div>Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.<div class="boxTitle">Conclusions</div>Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.</span> 63 10 1475 1478 10.1001/archneur.63.10.1475 http://archneur.jamanetwork.com/article.aspx?articleID=792501